Host-directed therapies for COVID-19.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
pubmed:
26
2
2021
medline:
14
4
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management. The use of umbilical cord-derived mesenchymal stem cells as HDT for COVID-19 has been shown to be safe in phase 1 and 2 trials. Trials of anti-interleukin-6 receptor antibodies show promising mortality benefit in hospitalized COVID-19 patients. Repurposed drugs and monoclonal antibodies targeting specific cytokines acting on different aspects of the pro- and anti-inflammatory cascades are under evaluation. A range of HDTs shows promise for reducing mortality and improving long term disability in patients with severe COVID-19, and require evaluation in randomized, controlled trials.
Identifiants
pubmed: 33629969
doi: 10.1097/MCP.0000000000000769
pii: 00063198-202105000-00011
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-209Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 2020; 395:497–506.
World Health Organization. COVID-19 dashboard: https://covid19.who.int/ . [Accessed 12 February 2021]
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; 323:2052–2059.
Li G, Fan Y, Lai Y. Coronavirus infections and immune responses. J Med Virol 2020; 92:424–432.
Song JW, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun 2020; 11:3410doi: 10.1038/s41467-020-17240-2.
doi: 10.1038/s41467-020-17240-2
Heiss R, Grodzki DM, Horger W, et al. High-performance low field MRI enables visualization of persistent pulmonary damage after COVID-19. Magn Reson Imaging 2021; 76:49–51. doi: 10.1016/j.mri.2020.11.004.
doi: 10.1016/j.mri.2020.11.004
Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 2020; 395:e35–e36. doi: 10.1016/S0140-6736(20)30305-6.
doi: 10.1016/S0140-6736(20)30305-6
Zumla A, Wang FS, Ippolito G, et al. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of mesenchymal stromal (stem) cell (MSC) therapy − achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis 2020; 96:431–439. doi: 10.1016/j.ijid.2020.05.040.
doi: 10.1016/j.ijid.2020.05.040
Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther 2020; 5:172doi: 10.1038/s41392-020-00286-5.
doi: 10.1038/s41392-020-00286-5
Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med 2020; doi: 10.1007/s11684-020-0810-9.
doi: 10.1007/s11684-020-0810-9
Shi L, Huang H, Lu X, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomised, double-blind, placebo controlled phase 2 trial. Signal Transduct Targeted Ther 2021; 6:58doi: 10.1038/s41392-021-00488-5.
doi: 10.1038/s41392-021-00488-5
Payares-Herrera C, Martínez-Muñoz ME, Vallhonrat IL, et al. Double-blind, randomized, controlled, trial to assess the efficacy of allogeneic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): a structured summary of a study protocol for a randomised controlled trial. Trials 2021; 22:9doi: 10.1186/s13063-020-04964-1.
doi: 10.1186/s13063-020-04964-1
Gorman E, Shankar-Hari M, Hopkins P, et al. Repair of acute respiratory distress syndrome by stromal cell administration in COVID-19 (REALIST-COVID-19): a structured summary of a study protocol for a randomised, controlled trial. Trials 2020; 21:462doi: 10.1186/s13063-020-04416-w.
doi: 10.1186/s13063-020-04416-w
Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 2020; 8:1233–1244.
Castelnovo L, Tamburello A, Lurati A, et al. Anti-IL6 treatment of serious COVID-19 disease: a monocentric retrospective experience. Medicine 2021; 100:e23582doi: 10.1097/MD.0000000000023582.
doi: 10.1097/MD.0000000000023582
Rajendram P, Sacha GL, Mehkri O, et al. Tocilizumab in coronavirus disease 2019-related critical illness: a propensity matched analysis. Crit Care Explor 2021; 3:e0327doi: 10.1097/CCE.0000000000000327.
doi: 10.1097/CCE.0000000000000327
Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med 2021; 384:20–30.
Stone JH, Frigault MJ, Serling-Boyd NJ, et al. BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med 2020; 383:2333–2344.
Horby PW, Campbell M, Staplin N, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1 . [Accessed 12 Februray 2021]
Veiga VC, Prats JAGG, Farias DLC, et al. Coalition COVID-[19] Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 2021; 372:n84doi: 10.1136/bmj.n84.
doi: 10.1136/bmj.n84
de Sousa E, Ligeiro D, Lérias JR, et al. Mortality in COVID-19 disease patients: correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. Int J Infect Dis 2020; 98:454–459.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–1062.